Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Unpacking Iberdomide's FDA Approval and The Future of CELMoDs

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 7 September 2026 · Fusion42 review

The FDA granted accelerated approval to iberdomide, the first CELMoD drug for relapsed/refractory multiple myeloma, marking a pivotal moment for targeted oral therapies in hematology.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 1 Sep 2026 and 7 Sep 2026.

◆ ◆ The Wire takeaway

You must prioritise integrating oral CELMoDs as a frontline or bridging therapy in multiple myeloma, as this approval unlocks new treatment pathways beyond hospital-based immunotherapies.

◆ Coverage

2 sources · first reported 1 Sep 2026 · latest 7 Sep 2026

◆ Related on Wire

◆ Topics

Biotechcelmodsmultiple-myelomafda-approvaloncologyoral-therapy